


## *Appendix 1*

### The BENEDICT Study Organization.

Members of the BENEDICT Study Organization were as follows (all in Italy unless otherwise noted): Principal investigator — G. Remuzzi (Bergamo); Study coordinator — P. Ruggenti (Bergamo); Coordinating center — Mario Negri Institute for Pharmacological Research, Clinical Research Center for Rare Diseases Aldo e Cele Daccò, Villa Camozzi, Ranica (Bergamo); Participating centers — G. Nastasi, A. Ongaro, F. Querci, A. Anabaya (Alzano Lombardo); R. Trevisan, A.R. Dodesini, G. Lepore, I. Nosari, C. A. Aros Espinoza, A. Fassi (Bergamo); M. Songini, G. Carta, G. Piras (Cagliari); B. Minetti, P. Fiorina, G. Ghilardi, V. Grassia, E. Pezzali, E. Seghezzi, I. Villanova (Clusone); A. Spalluzzi, I. Codreanu, C. Flores (Ponte San Pietro, Villa d'Almè); C. Chiurciu, F. Arnoldi, L. Mosconi, M. Monducci (Ranica); A. Bossi, M. Facchetti, V. Brusegan (Romano di Lombardia); F. Inversi, V. Bertone, R. Mangili, S. Bruno (Seriate); A. Bossi, A. Parvanova, I.P. Iliev, E. Terzieva (Treviglio); Ophthalmologists — M. Filipponi, I.P. Iliev, S. Tadini (Bergamo); Monitoring and drug distribution (Mario Negri Institute) — G. Gherardi, N. Rubis, S. Birolini, L. Bruni, W. Calini, V.A. Carrasco Oyarzun, R. D'Adda, O. Diadei, M. Ferrari, L. Mangili, A. Milani, G. Noris, K. Pagani, S. Quadri, A. Rossi, S. Secomandi, G. Villa (Ranica); Carriers (Mario Negri Institute) — G. Gaspari, S. Gelmi, G. Gervasoni (Ranica); Database and Data Validation (Mario Negri Institute) — A. Remuzzi, B. Ene-Iordache, V. Gambarà (Ranica); Data Analysis (Mario Negri Institute) — A. Perna, N. Motterlini, M. Ganeva, J. Zamora, B.D. Dimitrov (Ranica); Laboratory Measurements (Mario Negri Institute) — F. Gaspari, F. Carrara, E. Centemerì, S. Ferrari, M. Pellegrino, N. Stucchi, C. Petrò, C. Locatelli, A. Cannata, E. Savoldelli (Ranica); Genomic Evaluations (Mario Negri Institute) — M. Noris, P. Bettinaglio, S. Bucchioni, J. Caprioli, B. Giussani (Bergamo); Regulatory Affairs (Mario Negri Institute) — P. Boccardo (Ranica); Steering Committee — L. Minetti (Bergamo), G. Remuzzi (Bergamo), U.F. Legler (Ludwigshafen, Germany), B. Kalsch (Ludwigshafen, Germany), D. Nehrlich (Ludwigshafen, Germany), A. Nicolucci (S. Maria Imbaro), A. Perna (Bergamo), P. Ruggenti (Bergamo); Safety Committee — G.L. Bakris (Chicago, United States), R. Kay (Sheffield, United Kingdom), G.C. Viberti (London, United Kingdom).

Appendix 2

Study profile.



Appendix 3

Baseline and follow-up systolic and diastolic blood pressure (upper panel), HbA1c (middle panel), and blood glucose (lower panel) in patients on ACE inhibitor therapy with trandolapril (ACEi YES) or on non-ACE inhibitor therapy (ACEi NO). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  vs ACE YES at the same time point.

